Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors

Biochemical Pharmacology

Volumn 67, Issue 12, 2004, Pages 2175-2186

  Kubota, Toshio ^a   Fujisaki, Koji ^a   Itoh, Yoshinori ^a   Yano, Takahisa ^a   Sendo, Toshiaki ^a   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

2 (2 methoxy 4 nitorophenyl) 3 (4 nitorophenyl) 5 (2,4 disulfophenyl) 2H tetrazolium monosodium salt; 3 hydroxy 3 methyglutaryl coenzyme A; geranylgeranyl pyrophosphate; GGPP; HMG CoA; mevalonate; MVA; TUNEL; WST 8

Indexed keywords

ATORVASTATIN; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CERIVASTATIN; CHOLESTEROL; DNA FRAGMENT; DNA NUCLEOTIDYLEXOTRANSFERASE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOCORTIN 5; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; MITOCHONDRIAL ENZYME; PRAVASTATIN; PROTEIN BAX; PROTEIN BCL 2; SIMVASTATIN;

APOPTOSIS; ARTICLE; CELL COUNT; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROPHILICITY; LIPOPHILICITY; LIVER CELL CULTURE; LIVER INJURY; MEDICAL ASSESSMENT; NICK END LABELING; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION;

ADULT; ANNEXIN A5; APOPTOSIS; CASPASE 3; CASPASES; CHOLESTEROL; ENZYME INHIBITORS; HEPATOCYTES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN SITU NICK-END LABELING; PRAVASTATIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; RNA, MESSENGER; SIMVASTATIN;

EID: 2442434564     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.02.037     Document Type: Article

References (52)

1. Havel R.J., Rapaport E. Management of primary hyperlipidemia. New Engl. J. Med. 332:1995;1491-1498
2. Jukema J.W., Bruschke A.V., Van Boven A.J., Reiber J.H., Bal E.T., Zwinderman A.H., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540
3. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622
4. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. 128:2002;159-168
5. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA. 289:2003;1681-1690
6. Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., Didangelos T.P., Carina M.V., Kranitsas D.F., et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am. J. Cardiol. 80:1997;608-613
7. Gotto A.M. Jr. Risks and benefits of continued aggressive statin therapy. Clin. Cardiol. 26(Suppl):2003;3-12
8. Taher T.H., Dzavik V., Reteff E.M., Peason G.J., Woloschuk B.L., Francis G.A. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am. J. Cardiol. 89:2002;390-394
9. Hsu I., Spinler S.A., Johnson N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann. Pharmacother. 29:1995;743-759
10. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Downton M., Franklin F.A., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern Med. 151:1991;43-49
11. Ellen R.L., McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am. J. Cardiol. 81:1998;60B-65B
12. Maiguma T., Fujisaki K., Itoh Y., Makino K., Teshima D., Takahashi F., et al. Cell-specific degeneration induced by fibrates in human embryonal rhabdomyosarcoma cells. Naunyn-Schmiedeberg's Arch Pharmacol. 367:2003;289-296
13. Ogata Y., Takahashi M., Takeuchi K., Ueno S., Mano H., Ookawara S., et al. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. J. Cardiovasc. Pharmacol. 40:2002;907-915
14. Baetta R., Donetti E., Comparato C., Calore M., Rossi A., Teruzzi C., et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol. Res. 36:1997;115-121
15. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res. 83:1998;490-500
16. Guijarro C., Blanco-Colio L.M., Massy Z.A., O'Donnell M.P., Kasiske B.L., Keane W.F., et al. Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int. 71:1999;S88-S91
17. Li X., Liu L., Tupper J.C., Bannerman D.D., Winn R.K., Sebti S.M., et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J. Biol. Chem. 277:2002;15309-15316
18. Newton C.J., Ran G., Xie Y.X., Bilko D., Burgoyne C.H., Adams I., et al. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J. Endocrinol. 174:2002;7-16
19. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. 297:2001;861-867
20. Isobe I., Michikawa M., Yanagisawa K. Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid beta-protein and chloroquine in cultured rat astrocytes. Neurosci. Lett. 266:1999;129-136
21. Johnson J.D., Ahmed N.T., Luciani D.S., Han Z., Tran Z., Fujita J., et al. Increased islet apoptosis in Pdx1+/- mice. J. Clin. Invest. 111:2003;1147-1160
22. Beck M.T., Peirce S.K., Chen W.Y. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene. 21:2002;5047-5055
23. Lee E.H., Wan X.H., Song J., Kang J.J., Cho J.W., Seo K.Y., et al. Lens epithelial cell death and reduction of anti-apoptotic protein Bcl-2 in human anterior polar cataracts. Mol. Vision. 8:2002;235-240
24. Carr T.P., Andersen C.J., Rudel L.L. Enzymatic determination of triglyceride. Clin. Biochem. 26:1993;39-42
25. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254
26. van Engeland M., Ramaekers F.C., Schutte B., Reutelingsperger C.P. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry. 24:1996;131-139
27. Medema J.P., Scaffidi C., Kischkel F.C., Shevchenko A., Mann M., Krammer P.H., et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16:1997;2794-2804
28. Cha Y.J., Kim H.S., Rhim H., Kim B.E., Jeong S.W., Kim I.K. Activation of caspase-8 in 3-deazaadenosine-induced apoptosis of U-937 cells occurs downstream of caspase-3 and caspase-9 without Fas receptor-ligand interaction. Exp. Mol. Med. 33:2001;284-292
29. Ishiyama M., Miyazono Y., Sasamoto K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta. 44:1997;1299-1305
30. Fadok V.A., Voelker D.R., Campbell P.A., Cohen J.J., Bratton D.L., Henson P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148:1992;2207-2216
31. Van Heerde W.L., Robert-Offerman S., Dumont E., Hofstra L., Doevendans P.A., Smits J.F., et al. Markers of apoptosis in cardiovascular tissues: focus on Annexin V. Cardiovasc. Res. 45:2000;549-559
32. Salvesen G.S., Dixit V.M. Caspases: intracellular signaling by proteolysis. Cell. 91:1997;443-446
33. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316
34. Stennicke H.R., Jurgensmeier J.M., Shin H., Deveraux Q., Wolf B.B., Yang X., et al. Pro-caspase-3 is a major physiologic target of caspase-8. J. Biol. Chem. 273:1998;27084-27090
35. Kim T.H., Zhao Y., Barber M.J., Kuharsky D.K., Yin X.M. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. J. Biol. Chem. 275:2000;39474-39481
36. Yin X.M. Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res. 10:2000;161-167
37. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Ann. Rev. Cell Dev. Biol. 15:1999;269-290
38. Yin X.M., Wang K., Gross A., Zhao Y., Zinkel S., Klocke B., et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 400:1999;886-891
39. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 12:2000;611-620
40. Knapp A.C., Huang J., Starling G., Kiener P.A. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 152:2000;217-227
41. Tanaka T., Tatsuno I., Uchida D., Moroo I., Morio H., Nakamura S., et al. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J. Neurosci. 20:2000;2852-2859
42. Skulachev V.P. Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 423:1998;275-280
43. Cao G., Minami M., Pei W., Yan C., Chen D., O'Horo C., et al. Intracellular Bax translocation after transient cerebral ischemia: implications for a role of the mitochondrial apoptotic signaling pathway in ischemic neuronal death. J. Cereb. Blood Flow Metab. 21:2001;321-333
44. Sawada M., Nakashima S., Banno Y., Yamakawa H., Hayashi K., Takenaka K., et al. Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Cell. Death Differ. 7:2000;761-772
45. Ly J.D., Grubb D.R., Lawen A. The mitochondrial membrane potential (Δψm) in apoptosis; an update. Apoptosis. 8:2003;115-128
46. Gross A., Jockel J., Wei M.C., Korsmeyer S.J. Enforced dimerization of BAX results in its translocation. EMBO J. 17:1998;3878-3885
47. Blanco-Colio L.M., Vill A.A., Ortego M., Hernandez-Presa M.A., Pascual A., Plaza J.J., et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 161:2002;17-26
48. Hippenstiel S., Schmeck B., N'Guessan P.D., Seybold J., Krull M., Preissner K., et al. Rho protein inactivation induced apoptosis of cultured human endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 283:2002;L830-L838
49. Gomez J., Martinez C., Giry M., Garcia A., Rebollo A. Rho prevents apoptosis through Bcl-2 expression: implications for interleukin-2 receptor signal transduction. Eur. J. Immunol. 27:1997;2793-2799
50. Serajuddin A.T., Ranadive S.A., Mahoney E.M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80:1991;830-834
51. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19:1998;26-37
52. Biswas K.K., Sarker K.P., Abeyama K., Kawahara K., Iino S., Otsubo Y., et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology. 38:2003;1167-1177